Table 2.
Chemotherapy regimens and responses.
| MDT cohort, N = 229(%) | Non-MDT cohort, N = 294 (%) | p value | |
|---|---|---|---|
| No. of patients receiving pre-operative CT | 159 (69.4) | 211 (71.7) | 0.006 |
| Regimens | |||
| Oxaliplatin-containing regimens | 79 (49.7) | 103 (48.8) | 0.118 |
| Irinotecan-containing regimens | 67 (42.1) | 74 (35.1) | 0.166 |
| Oxaliplatin and irinotecan containing regimens (triplet) | 10 (6.3) | 31 (14.7) | 0.011* |
| Monochemoterapy with fluoropyrimidines | 3 (1.9) | 3 (1.4) | 0.726 |
| Biological agents | |||
| Anti-VEGF | 53 (33.3) | 70 (33.1) | 0.980 |
| Anti-EGFR | 52 (32.7) | 34 (16.1) | < 0.0001* |
| Median number of cycles (range) | 8 (2–24) | 10 (1–38) | 0.002* |
| Radiological response to chemotherapy | |||
| Complete response (CR) | 1 (0.6) | 0 | 0.257 |
| Partial response (PR) | 129 (81.1) | 128 (60.7) | 0.004* |
| Stable disease (SD) | 19 (12) | 32 (15.2) | 0.322 |
| Progressive disease (PD) | 10 (6.3) | 51 (24.1) | < 0.0001* |
CT chemotherapy.
*Statistically significant.